ArticleMolecules (Basel, Switzerland)2026
Preparation of Platycodin D Microspheres and Their Protective Effects on Type 2 Diabetes Mellitus.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The treatment of type 2 diabetes (T2DM) faces numerous challenges. Oral insulin (Ins) and other short-acting compounds still encounter significant obstacles in the hostile gastrointestinal environment, including low bioavailability and rapid metabolic clearance. Platycodin D (PD) is a natural compound with demonstrated hypoglycemic and lipid-lowering effects. In this study, PD was encapsulated using alginate to prepare orally administrable, pH-responsive, gut-targeted gel microspheres (PD@MPs), and their efficacy in improving T2DM prognosis was investigated. In vitro release studies demonstrated that PD@MPs avoided degradation by gastric acid and were released in the intestine. Cell experiments indicated that PD possessed significant antioxidant and anti-apoptotic properties. Masson, immunohistochemistry, and immunofluorescence staining revealed that PD@MPs alleviated inflammation in key metabolic organs and maintained normal pancreatic tissue function and morphology. Western blot analysis assessed the expression of proteins related to hepatic glycogen synthesis, including IRS-1, GLUT2, GSK-3β, and AKT. The research results indicate that the assembly strategy using sodium alginate (SA) as the coating layer has enabled the oral administration of PD and has demonstrated its potential in the treatment of diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.